Cargando…
Use of Eflornithine (DFMO) in the Treatment of Early Alzheimer's Disease: A Compassionate Use, Single-Case Study
Background: Recent genome-wide association screening (GWAS) studies have linked Alzheimer's disease (AD) neuropathology to gene networks that regulate immune function. Kan et al. recently reported that Arg1 (an anti-inflammatory gene that codes for arginase-1) is expressed in parts of the brain...
Autores principales: | Alber, Jessica, McGarry, Kelly, Noto, Richard B., Snyder, Peter J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845715/ https://www.ncbi.nlm.nih.gov/pubmed/29559907 http://dx.doi.org/10.3389/fnagi.2018.00060 |
Ejemplares similares
-
DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27(Kip1) activity in neuroblastoma
por: KOOMOA, DANA-LYNN T., et al.
Publicado: (2013) -
Difluoromethylornithine (DFMO) and Neuroblastoma: A Review
por: Tangella, Adarsh Vardhan, et al.
Publicado: (2023) -
Maintenance DFMO Increases Survival in High Risk Neuroblastoma
por: Sholler, Giselle L. Saulnier, et al.
Publicado: (2018) -
Enantiospecific antitrypanosomal in vitro activity of eflornithine
por: Boberg, Mikael, et al.
Publicado: (2021) -
A Molecular Mechanism for Eflornithine Resistance in African Trypanosomes
por: Vincent, Isabel M., et al.
Publicado: (2010)